Navigating the Therapeutic Roller Coaster of COVID-19: Lessons for the Future.
Sudhir Chandra Sarangi, Deeksha Sharma
Author Information
- Sudhir Chandra Sarangi: Additional Professor, Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.
- Deeksha Sharma: PhD Scholar, Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.
No abstract text available.
- Number of clinical trial registrations by location, disease, phase of development, age and sex of trial participants (1999-2022). World Health Organization 2023 Available from: https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/number-of-trial-registrations-by-year-location-disease-and-phase-of-development [Last accessed on 2023 Oct 26].
- Coronavirus (COVID-19) |Drugs. U. S. Food &Drug Administration 2023 Available from: https://www.fda.gov/drugs/emergency-preparedness-drugs/coronavirus-covid-19-drugs [Last accessed on 2023 Oct 26].
- Di Stefano L, Ogburn EL, Ram M, Scharfstein DO, Li T, Khanal P, et al. Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19:An individual participant data meta-analysis. PLoS One 2022;17:e0273526.
- Bartoli A, Gabrielli F, Alicandro T, Nascimbeni F, Andreone P. COVID-19 treatment options:A difficult journey between failed attempts and experimental drugs. Intern Emerg Med 2021;16:281–308.
- Popp M, Reis S, Schießer S, Ilona Hausinger R, Stegemann M, Metzendorf MI, et al. Ivermectin for preventing and treating COVID-19. Emergencias 2023;35:381–3.
Humans
COVID-19
SARS-CoV-2
India
COVID-19 Drug Treatment
